CN113845484A - Novel quinazoline small molecule inhibitor and application thereof in antitumor drugs - Google Patents
Novel quinazoline small molecule inhibitor and application thereof in antitumor drugs Download PDFInfo
- Publication number
- CN113845484A CN113845484A CN202111046514.7A CN202111046514A CN113845484A CN 113845484 A CN113845484 A CN 113845484A CN 202111046514 A CN202111046514 A CN 202111046514A CN 113845484 A CN113845484 A CN 113845484A
- Authority
- CN
- China
- Prior art keywords
- nmr
- ppm
- dmso
- compound
- hrms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 title claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 5
- -1 quinazoline small molecule Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims abstract description 26
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 239000003560 cancer drug Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 140
- 238000005160 1H NMR spectroscopy Methods 0.000 description 44
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 41
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 108091005625 BRD4 Proteins 0.000 description 7
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004900 autophagic degradation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 230000004908 autophagic flux Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical class OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种双靶向BRD4‑CK2小分子抑制剂及其在抗三阴性乳腺癌药物中的应用，属于抗肿瘤药学技术领域。本发明解决的技术问题是提供一种作为双靶向BRD4‑CK2小分子抑制剂的化合物。该化合物包括如下所示的化合物及其药学上可接受的盐，本发明的化合物或其药学上可接受的盐，可以作为双靶向BRD4‑CK2抑制剂，具有一定抗三阴性乳腺癌活性，能有效抑制三阴性乳腺癌细胞的生长。
The invention relates to a double-targeted BRD4-CK2 small molecule inhibitor and its application in anti-triple-negative breast cancer drugs, belonging to the technical field of anti-tumor pharmacy. The technical problem solved by the present invention is to provide a compound that acts as a dual-targeted BRD4-CK2 small molecule inhibitor. The compound includes the following compounds and pharmaceutically acceptable salts thereof. The compounds of the present invention or their pharmaceutically acceptable salts can be used as dual-targeted BRD4-CK2 inhibitors and have certain anti-triple-negative breast cancer activity, Can effectively inhibit the growth of triple negative breast cancer cells.
Description
Technical Field
The invention discloses a double-targeting BRD4-CK2 small molecule inhibitor and application thereof in tumor treatment, belonging to the technical field of antitumor medicine.
Background
Recent statistics by the international cancer research center indicate that about 170 million women are diagnosed with breast cancer every year worldwide and result in the death of 50 million patients. In China, breast cancer has a high rate of growth of about 4% in recent years, and has a trend of further rejuvenation, seriously threatening the health of women. Triple Negative Breast Cancer (TNBC) refers to breast cancer which is negative for Estrogen Receptor (ER), progestational hormone receptor (PR) and human epidermal growth factor receptor 2(Her-2), accounts for 15-20% of all breast cancer pathological types, and has extremely high lethality rate. Due to the special biological behavior and clinical pathological characteristics of TNBC, the prognosis of TNBC is worse than that of other types of breast cancer, and the TNBC has the characteristics of high malignancy, younger onset age, high invasiveness, easy relapse and transfer and the like. Because ER, PR are not expressed and there is a lack of HER2 amplification, TNBC generally has no recognized molecular therapeutic targets and lacks clinically effective therapeutic drugs and therapeutic strategies.
The TNBC treatment means commonly used in clinic at present are still surgery and conventional systemic cytotoxic chemical treatment, the treatment effect is not ideal, and the prognosis is still poor. Bromodomain accompanying protein 4(BRD4) has an attractive epigenetic target in cancer and other chronic diseases. More and more BRD4 inhibitors are being discovered and used in the treatment of TNBC, but the emergence of drug resistance is the most major problem limiting the clinical use of BRD4 inhibitors. The protein kinase casein kinase 2(CK2) is a molecular switch that mediates BRD4 phosphorylation and dephosphorylation and thus functions. In addition, CK2 inhibition also results in increased uptake of known drugs by multidrug resistant cells. Therefore, designing synthetic dual-targeting inhibitors of BRD4-CK2 may provide new strategies for TNBC therapy.
Disclosure of Invention
The technical problem solved by the invention is to provide a novel compound serving as a dual-targeting BRD4-CK2 inhibitor.
A compound of formula I or formula II:
wherein R is1Is 3,5-diCH3H or 3, 5-diBr; r2Is 4-F, 4-OCH34-Cl, 5-Cl or 5-CH3；R3Is composed of
The invention also provides application of the compound or the pharmaceutically acceptable salt thereof in preparing antitumor drugs.
Further, the anti-tumor therapeutic drug is preferably a triple negative breast cancer therapeutic drug.
Further, the triple negative breast cancer treatment drug is a double-targeting BRD4-CK2 small molecule inhibitor, and the application of the triple negative breast cancer treatment drug is used for triple negative breast cancer related treatment.
The present invention also provides a pharmaceutical composition which is a preparation comprising an effective dose of the above-mentioned compound or a pharmaceutically acceptable salt thereof.
The compound or the pharmaceutically acceptable salt thereof prepared by the invention can be used as a double-target BRD4-CK2 small molecule inhibitor, and has a relatively obvious triple negative breast cancer treatment effect.
Drawings
FIG. 1A is a picture of the autophagy flux changes observed under an inverted microscope after transfection of MDA-MB-231 cells with autophagy double-standard adenovirus GFP-mRFP-LC3, and treatment with 5. mu.M Compound 32(44e) for 24 hours.
FIG. 1B 44e is a picture of the inhibition of colony formation in MDA-MB-231 cells at 0. mu.M, 2.5. mu.M, 5. mu.M and 10. mu.M concentrations.
FIG. 1C 44e is a graph of MDA-MB-231 cell death promoted at 0. mu.M, 2.5. mu.M, 5. mu.M and 10. mu.M concentrations.
FIG. 1D 44e is a picture showing that MDA-MB-231 cells promoted apoptosis at 0. mu.M and 5. mu.M concentrations.
FIG. 2A is a photograph showing the change in tumor volume of nude mice by oral administration of 44e to a nude mouse model of MDA-MB-231 xenograft.
FIG. 2B photographs of the change in tumor volume of nude mice xenografted with MDA-MB-468 by oral administration of 44 e.
Detailed Description
The present invention provides compounds of formula I or formula II:
wherein R is1Is 3,5-diCH3H or 3, 5-diBr; r2Is 4-F, 4-OCH34-Cl, 5-Cl or 5-CH3；R3Is composed of
As a preferred embodiment, R is preferred1Is H; r3Is composed of
More preferably R1Is H; r3Is composed of
The following are some preferred structures of the compounds of the present invention.
The invention also provides pharmaceutically acceptable salts of the compounds of the invention. The salt may be nitrate, hydrochloride, sulfate or phosphate, etc.
The invention also provides application of the compound or the pharmaceutically acceptable salt thereof in preparing a medicament for treating triple negative breast cancer. Further, the triple negative breast cancer treatment drug is preferably a double-targeting BRD4-CK2 small molecule inhibitor.
The present invention also provides a pharmaceutical composition which is a preparation comprising an effective dose of the above-mentioned compound or a pharmaceutically acceptable salt thereof. The compounds of the invention can be prepared in the following forms by methods known in the art: tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or sprays for inhalation, sterile aqueous or oily solutions or suspensions or sterile emulsions for parenteral (including intravenous, intramuscular or infusion). The liquid formulations can be prepared using sterile water or water-propylene glycol solutions as solvents, or the active ingredient can be formulated in aqueous polyethylene glycol solutions. Aqueous solutions for oral administration can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be prepared by dispersing the finely divided active component in water together with viscous materials such as natural synthetic gums, resins, methyl cellulose, carboxymethyl cellulose and other suspending agents known in the pharmaceutical arts.
The pharmaceutical composition may be in unit dosage form. In these forms, the composition is divided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form can be a packaged preparation comprising discrete quantities of the preparation, such as tablets, capsules, and powders in vials or ampoules . The unit dosage form can also be a capsule, cachet, or tablet or it can be the appropriate number of any of these packaged forms.
The active ingredient of the pharmaceutical composition of the present invention may be only the compound of the present invention, or may be combined with other anti-triple negative breast cancer compounds as an active ingredient.
In the treatment of triple negative breast cancer, such combination therapy may be achieved by the simultaneous, sequential or separate administration of the various therapeutic ingredients. Such combinations employ the compounds of the present invention in an effective dosage range and the other pharmaceutically active agents in a permitted dosage range.
The following examples are provided to further illustrate the embodiments of the present invention and are not intended to limit the scope of the present invention.
Example 1 Synthesis of Compounds 1-41.
Compounds 1-41 were synthesized using the following reaction scheme:
Reagents and conditions：(a)K2CO3，DMF，80℃，3h；(b)DCM，TFA，r.t，2h.；(c)DMAC，PTSA，NaHSO3，120℃，4-8h；(d)DMF，Et3N，HOBt，EDCI，r.t.；24h。
general procedure for the Synthesis of intermediates 1 a-c.
Tert-butyl bromoacetate (3.0mL, 1.2equiv) and p-hydroxybenzaldehyde analog (2.5g, 1equiv) were dissolved in DMF (10mL) and 5.2g K was added2CO3The reaction was carried out at 80 ℃ for 1.5 h. After cooling the reaction, 80mL of water was added, filtered and dried to give the crude product, which was purified by silica gel column Chromatography (CH)2Cl2/CH3OH 80: 1-5: 1) to give intermediates 1a-c (55-60% yield) without further purification.
Intermediate (1a)1H-NMR(400MHz，CD3OD)，δ(ppm)：9.84(1H，s)，7.86(2H，d，J＝8.8Hz)，7.06(2H，d，J＝8.8Hz)，4.71(2H，s)，1.48(9H，s)。HRMS(ESI)+Calculated for C13H17O3，[M+H]+：m/z 221.1178，found 221.1170。
General procedure for the Synthesis of intermediates 2 a-c.
Intermediates 1a-c (2g, 9mmol) were dissolved in CH2Cl2(5mL), TFA (1.5mL) was added dropwise, and the reaction was carried out at room temperature for 1 h. The reaction was concentrated under reduced pressure to afford intermediates 2a-c (72-77% yield) as white solids without further purification.
Intermediate (2a)1H-NMR(400MHz，CD3OD)，δ(ppm)：12.28(1H，s)，9.82(1H，s)，7.84(2H，d，J＝8.8Hz)，7.04(2H，d，J＝8.8Hz)，3.68(2H，s)。HRMS(ESI)+Calculated for C9H9O4，[M+H]+：m/z 181.0501，found 181.0507。
Intermediate 2a (0.9mmol, 1equiv) and benzaldehyde derivative (0.9mmol, 1equiv) were dissolved in DMAc (15 mL)) Adding NaHSO4(1.05mmol, 1.2equiv) and PTSA (0.22mmol, 0.24 equiv). The reaction mixture was stirred at 120 ℃ under reflux for 4-6 h. After completion of the reaction, water (100mL) was added to the reaction, and the precipitate was obtained by filtration. Purification of the solid by column chromatography on silica gel (CH)2Cl2/CH3OH 80: 1-10: 1) to yield intermediates 3a-h, respectively (41-65% yield).
Intermediate (3a)1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.97(1H，s)，8.13(2H，d，J＝8.8Hz)，7.04(2H，d，J＝8.8Hz)，6.72(1H，d，J＝2.0Hz)，6.51(1H，d，J＝2.0Hz)，4.79(2H，s)，3.88(3H，s)，3.84(3H，s)。HRMS(ESI)+Calculated for C18H16NaN2O6，[M+Na]+：m/z 379.0906，found 379.0910。
Dissolving the intermediate 3a-h (0.42mmol, 1.2eq) in DMF (3mL), adding HOBT (0.54mmol, 1.3equiv) at 0 ℃, stirring for 10min, adding EDCI (0.54mmol, 1.3equiv), adding the reactant containing amino substitution, continuing the reaction, adding TEA (1.5mmol, 3.5equiv) for reaction at 0 ℃ for 1h, finally reacting at normal temperature for 24h, adding 80mL of water into the reaction solution, filtering and drying to obtain a crude product. Purification of the solid by column chromatography on silica gel (CH)2Cl2/CH3OH 30: 1-1: 1) to give 1-41 (43-66% yield), respectively, as the final product.
Compound 2, mp 265-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：9.39(1H，s)，8.81(1H，s)，7.92(2H，s)，6.69(1H，s)，6.45(1H，s)，4.60(1H，s)，4.25(2H，s)，3.87(3H，s)，3.63(3H，s)，3.64(4H，t，J＝4.4Hz)，2.82(4H，t，J＝4.4Hz)，2.30(6H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：169.3，164.8，163.6，160.7，158.1，157.4，153.7，130.4(2)，128.3(2)，128.2，105.0，100.7，97.0，70.5，65.9(2)，55.8，55.5，54.5(2)，16.1(2)。HRMS(ESI)+Calculated for C24H29N4O6，[M+H]+：m/z 469.2087，found469.2103。
Compound 5, mp 267-269 ℃, yield 45.5%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：9.50(1H，s)，8.50(2H，s)，6.80(1H，s)，6.57(1H，s)，4.48(2H，s)，3.90(3H，s)，3.86(3H，s)，3.45-3.47(2H，m)，3.07-3.08(2H，m)，2.75-2.77(2H，m)，2.97-2.99(2H，m)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.0，164.4，160.9，159.5，154.1，152.4，149.7，132.0(2)，131.2，117.6(2)，104.8，101.5，98.2，71.0，56.0，55.7，52.7(2)，43.5，42.6，28.8(2)。HRMS(ESI)+Calculated for C24H27Br2N2O5，[M+H]+：m/z 611.0328，found 611.0320。
Compound 8, mp 269-271 ℃, yield 63.7%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.07(1H，s)，8.15(2H，d，d，J＝8.8Hz)，7.13(2H，d，J＝8.8Hz)，7.06(2H，s)，6.74(1H，d，J＝2.4Hz)，6.53(1H，d，J＝2.4Hz)，4.80(2H，s)，3.89(3H，s)，3.85(3H，s)，3.74(6H，s)，3.62(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.0，164.4，161.0，160.7，159.5，153.0，152.7(2)，151.7，134.5，133.7，129.7(2)，124.2，114.7(2)，104.3，100.2，97.6，97.4(2)，67.1，60.1(2)，56.0，55.7(2)。HRMS(ESI)+Calculated for C27H27NaN3O8，[M+Na]+：m/z 544.1696，found 544.1694。
Compound 9, mp 240-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：9.98(1H，s)，7.92(2H，s)，7.18(2H，s)，6.76(1H，d，J＝2.4Hz)，6.54(1H，d，J＝2.4Hz)，4.48(2H，s)，3.89(3H，s)，3.85(3H，s)，3.75(6H，s)，3.63(3H，s)，2.36(6H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.3，164.4，161.0，159.5，157.8，152.8，152.7(2)，152.0，134.5，133.8，130.9(2)，128.6(2)，127.3，104.5，100.6，97.7，97.6(2)，71.0，60.1，56.0，55.8(2)，55.7，16.2(2)。HRMS(ESI)+Calculated for C29H31NaN3O8，[M+Na]+：m/z 572.2009，found 572.2007。
Compound 11, mp 244-246 ℃, yield 64.4%.1H-NMR(400MHz，CDCl3)，δ(ppm)：8.26(2H，d，J＝8.4Hz)，7.06(2H，d，J＝8.4Hz)，6.46(1H，d，J＝2.4Hz)，6.42(1H，d，J＝8.4Hz)，4.56(2H，s)，3.98(3H，s)，3.93(3H，s)，4.03-4.06(4H，m)，2.87(2H，t，J＝12.4Hz)，1.94(2H，t，J＝12.4Hz)，1.45(9H，s)；13C-NMR(100MHz，CDCl3)，δ(ppm)：166.9，165.4，161.9，161.5，159.9，154.7，152.2，129.8(2)，115.0(2)，104.9，101.1，98.5，79.9，67.5，56.6，55.9，46.7，42.8，42.5，32.1(2)，28.6(5)。HRMS(ESI)+Calculated for C28H35N4O7，[M+H]+：m/z 539.2506，found539.2514。
Compound 12, mp 236-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：8.13(1H，d，J＝8.4Hz)，7.90(2H，s)，6.72(1H，d，J＝2.4Hz)，6.48(1H，d，J＝2.4Hz)，4.26(2H，s)，3.91-3.93(2H，m)，3.89(3H，s)，3.83(3H，s)，3.31-3.33(2H，m)，2.80-2.82(2H，m)，2.29(6H，s)，1.70-1.72(2H，m)，1.39(9H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.8，164.0，161.9，160.9，160.5，157.6，153.9，153.2，152.9，130.6(2)，128.3(2)，104.8，100.9，97.4，78.6，70.8，55.9，55.5，45.7，42.7，42.2，31.2(2)，28.1(3)，16.1(2)。HRMS(ESI)+Calculated for C30H39N4O4，[M+Na]+：m/z 589.2638，found 589.2635。
Compound 13, mp 240-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.86(1H，s)，9.86(1H，s)，7.92(2H，s)，7.55(2H，d，J＝8.8Hz)，6.90(2H，d，J＝8.8Hz)，6.74(1H，d，J＝2.0Hz)，6.51(1H，d，J＝2.0Hz)，4.47(2H，s)，3.88(3H，s)，3.84(3H，s)，3.08(4H，t，J＝4.8Hz)，2.44(4H，t，J＝4.8Hz)，2.35(6H，s)，2.21(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：165.9，164.3，161.0，159.8，157.8，153.1，152.4，147.6，130.8(2)，130.2，128.4(2)，127.9，121.1(2)，115.6(2)，104.7，101.2，97.6，71.2，56.0，55.7，54.6(2)，48.5(2)，45.8，16.8(2)。HRMS(ESI)+Calculated for C31H36N5O5，[M+H]+：m/z 558.2716，found 558.2719.
Compound 14, mp 237-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.88(1H，s)，10.01(1H，s)，7.93(2H，s)，7.42(1H，s)，7.28(1H，t，J＝8.0Hz)，7.23(1H，t，J＝8.0Hz)，6.77(1H，d，J＝2.4Hz)，6.73(1H，s)，6.51(1H，d，J＝2.4Hz)，4.49(2H，s)，3.88(3H，s)，3.84(3H，s)，3.35-3.37(4H，m)，3.17(4H，s)，2.86(3H，s)，2.36(6H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.4，165.6，164.2，160.9，159.7，157.6，153.0，152.4，149.9，139.2，130.7(2)，129.3，128.3(2)，127.9，111.7，107.5，104.6，101.1，97.6，71.0，57.8，55.9，55.6，52.2(2)，45.7(2)，16.2(2)。HRMS(ESI)+Calculated for C31H35NaN5O5，[M+Na]+：m/z 580.2536，found580.2534。
Compound 15, mp 270-.1H-NMR(400MHz，AceticAcid-d4)，δ(ppm)：8.58(2H，s)，7.58(2H，d，J＝8.8Hz)，7.22(2H，d，J＝8.8Hz)，7.05(1H，d，J＝2.0Hz)，6.71(1H，d，J＝2.0Hz)，5.01(2H，s)，4.10(3H，s)，4.11(3H，s)，3.92(4H，t，J＝4.8Hz)，3.41(4H，t，J＝4.8Hz)，3.12(3H，s)；13C-NMR(100MHz，AceticAcid-d4)，δ(ppm)：168.7，167.8，164.9.0，163.1，156.1，154.8，151.0，148.8，133.9(2)，132.9，132.4，123.9(2)，119.7(2)，119.2(2)，105.7，103.0，100.2，72.6，57.2，57.1，54.7(2)，48.7(2)，44.3。HRMS(ESI)+Calculated for C29H30Br2N5O5，[M+H]+：m/z 688.0593，found 688.0596。
Compound 17, mp 256-258 ℃, yield 66.0%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.95(1H，s)，10.12(1H，s)，8.17(2H，d，J＝8.4Hz)，7.38(1H，s)，7.21(1H，t，J＝8.0Hz)，7.11-7.15(2H，m)，6.77(1H，dd，J＝8.0，2.4Hz)，6.72(1H，d，J＝2.4Hz)，6.52(1H，d，J＝2.0Hz)，4.82(2H，s)，3.85(3H，s)，3.82(3H，s)，3.74-3.76(2H，m)，3.51-3.53(2H，m)，3.16(2H，s)，2.96-2.98(2H，m)，2.86(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.8，166.6，164.7，161.5，160.9，153.5，152.9，150.5，139.8，129.9(2)，125.5，115.1(2)，112.3，112.0，107.8，105.0，101.5，97.9，89.7，67.5，56.0，55.7，52.7(2)，46.2(2)，42.5。HRMS(ESI)+Calculated for C29H31NaN5O5，[M+Na]+：m/z 552.2223，found 552.2222。
Compound 20, mp 264-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.87(1H，s)，9.91(1H，s)，7.92(2H，s)，7.34(1H，s)，7.15-7.23(2H，m)，6.74(1H，d，J＝2.4Hz)，6.69(1H，dd，J＝8.4，2.4Hz)，6.51(1H，d，J＝2.8Hz)，4.47(2H，s)，3.88(3H，s)，3.84(3H，s)，3.73(4H，t，J＝4.8Hz)，3.08(4H，t，J＝4.8Hz)，2.35(6H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：167.7，166.4，164.3，162.5，161.0，157.7，152.4，151.5，139.1，130.8(2)，129.1，128.4(2)，127.9，110.9(2)，106.，104.6，101.2，97.6，71.0，66.1(2)，56.0，55.7，48.5(2)，16.2(2)。HRMS(ESI)+Calculated for C30H32NaN4O6，[M+Na]+：m/z 567.2220，found 567.2211。
Compound 21, mp 242-244 ℃ and yield 49.7%.1H-NMR(400MHz，DMSO-d6+CF3COOD)，δ(ppm)：10.34(1H，s)，8.39(2H，s)，7.87(2H，d，J＝8.4Hz)，7.62(2H，d，J＝8.4Hz)，6.80(1H，d，J＝2.0Hz)，6.62(1H，d，J＝2.0Hz)，4.74(2H，s)，3.95(4H，t，J＝4.8Hz)，3.86(6H，s)，3.58(4H，t，J＝4.8Hz)；13C-NMR(100MHz，DMSO-d6+CF3COOD)，δ(ppm)：166.6，166.4，162.6，156.9，156.8，153.8，139.9，138.6，134.6(2)，122.5(2)，122.2(2)，118.6(2)，116.8，115.0，104.5，99.8，98.4，72.4，65.0(2)，57.0，56.6，55.4(2)。HRMS(ESI)+Calculated for C28H27Br2N4O6，[M+H]+：m/z 675.0277，found 675.0275。
Compound 22, mp 276-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.92(1H，s)，9.93(1H，s)，7.50(2H，d，J＝8.8Hz)，7.12(2H，d，J＝8.8Hz)，6.91(2H，d，J＝8.8Hz)，6.71(1H，d，J＝2.4Hz)，6.50(1H，d，J＝2.4Hz)，4.76(2H，s)，3.88(3H，s)，3.84(3H，s)，3.72(4H，t，J＝4.8Hz)，3.05(4H，t，J＝4.8Hz)；13C-NMR(100MHz，CDCl3+CF3COOD)，δ(ppm)：169.0，163.2，162.0，160.0，156.4，137.5，131.3，131.0，123.4，123.3，121.8，121.5，119.0，117.0，116.9，116.1，116.0，113.3，101.0，98.5，94.8，67.0，64.5，64.2，56.9，56.3，56.1(2)。HRMS(ESI)+Calculated for C28H29N4O4，[M+H]+：m/z 517.2087，found 517.2086。
The compound 23, mp 272-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.02(1H，s)，8.16(2H，d，J＝8.4Hz)，7.28(1H，t，J＝2.4Hz)，7.09-7.16(4H，m)，6.72(1H，d，J＝2.4Hz)，6.68(1H，dd，J＝8.4，2.4Hz)，6.51(1H，d，J＝2.4Hz)，4.79(2H，s)，3.88(3H，s)，3.84(3H，s)，3.72(4H，t，J＝4.8Hz)，3.06(4H，t，J＝4.8Hz)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.1(2)，164.3，161.0，160.5，152.9，152.5，151.5，139.2，129.4(2)，129.2，125.0，114.6(2)，110.9，110.7，106.4，104.5，100.9，97.5，67.1，66.1(2)，56.0，55.6，48.5(2)，。HRMS(ESI)+Calculated for C28H29N4O6，[M+H]+：m/z 517.2087，found 517.2053。
Compound 24, mp 265-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.87(1H，s)，9.58(1H，s)，7.92(2H，s)，7.53(2H，d，J＝8.8Hz)，6.89(2H，d，J＝8.8Hz)，6.74(1H，s)，6.52(1H，s)，4.45(2H，s)，3.89(3H，s)，3.84(3H，s)，3.06-3.08(4H，m)，2.35(6H，s)，1.58-1.63(4H，m)，1.51-1.52(2H，m)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：165.8，164.2，160.9，157.8，153.1，152.4，148.4，130.8(2)，129.9，128.7(2)，127.9，121.1(2)，116.1(2)，104.7，101.2，97.6，71.1，56.0，55.6，50.0(2)，35.8，25.3(2)，23.9，16.2(2)。HRMS(ESI)+Calculated for C31H35N4O5，[M+H]+：m/z 543.2607，found 535.2607。
Compound 25, mp 271-273 ℃, yield 62.0%.1H-NMR(400MHz，DMSO-d6+CF3COOD)，δ(ppm)：10.48(1H，s)，8.52(2H，s)，7.94(2H，d，J＝8.8Hz)，7.73(2H，d，J＝8.8Hz)，6.85(1H，d，J＝2.4Hz)，6.65(1H，d，J＝2.4Hz)，4.78(2H，s)，3.93(3H，s)，3.91(3H，s)，3.58-3.61(4H，m)，1.94-1.97(4H，m)，1.70(2H，s)；13C-NMR(100MHz，DMSO-d6+CF3COOD)，δ(ppm)：166.0，165.4，165.3，161.7，155.2，151.8，142.1，139.8，138.2，133.2(2)，122.4(2)，121.5，121.4(2)，118.0(2)，104.6，99.8，98.9，71.7，56.8(2)，56.5，56.1，23.8(2)，21.0。HRMS(ESI)+Calculated for C29H29Br2N4O5，[M+H]+：m/z 673.0484，found 673.0490。
Compound 26, mp 253-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.93(1H，s)，9.89(1H，s)，8.17(2H，d，J＝8.8Hz)，7.45(1H，d，J＝8.8Hz)，7.12(2H，d，J＝8.8Hz)，6.88(1H，d，J＝8.8Hz)，6.71(1H，d，J＝2.4Hz)，6.51(1H，d，J＝2.4Hz)，4.75(2H，s)，3.88(3H，s)，3.84(3H，s)，3.04-3.07(4H，m)，1.57-1.62(4H，m)，1.50-1.51(2H，m)；13C-NMR(100MHz，DMSO-d6+CF3COOD)，δ(ppm)：166.6，165.8，162.8，161.9，157.6，156.4，144.2，139.7，137.9，131.7(2)，122.3(2)，120.9，120.8(2)，119.2，115.3(2)，103.1，98.7，96.1，67.2，56.5(2)，56.2，23.6(2)，20.8。HRMS(ESI)+Calculated for C29H31N4O5，[M+H]+：m/z 515.2294，found 515.2300。
Compound 27, mp 243-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：9.80(1H，s)，8.16(2H，d，J＝9.2Hz)，7.42(2H，d，J＝9.2Hz)，7.14(2H，d，J＝8.8Hz)，6.72(1H，d，J＝2.4Hz)，6.50-6.53(2H，m)，4.74(2H，s)，3.89(3H，s)，3.85(3H，s)，3.17-3.19(4H，m)，1.92-1.95(4H，m)；13C-NMR(100MHz，DMSO-d6+CF3COOD)，δ(ppm)：166.2，163.2，162.1(2)，157.3，156.9，143.3，141.4，132.0(2)，121.1(2)，119.9，119.8(2)，118.6，115.5(2)，103.0，98.9，95.6，67.4，56.8，56.3，55.3(2)，23.9(2)。HRMS(ESI)+Calculated for C28H29N4O5，[M+H]+：m/z 501.2138，found 501.2133。
Compound 28, mp 258-260 ℃, yield 55.9%.1H-NMR(400MHz，DMSO-d6+CF3COOD)，δ(ppm)：7.80(1H，dd，J＝14.0，2.4Hz)，7.68(2H，s)，7.47(1H，dd，J＝9.2，2.4Hz)，7.36(1H，t，J＝9.2Hz)，6.83(1H，d，J＝2.0Hz)，6.55(1H，d，J＝2.0Hz)，4.46(2H，s)，3.82-3.85(4H，m)，3.81(3H，s)，3.78(3H，s)，3.34-3.36(4H，m)，2.30(6H，s)；13C-NMR(100MHz，DMSO-d6+CF3COOD)，δ(ppm)：169.2，168.8，164.3，162.6，159.3，158.9，155.8(250.2Hz)，143.9，134.7(2)，130.6(2)，132.6(2)，126.4，126.2，124.6，122.9，104.8，101.2，97.0，72.7，65.9，65.5，58.0，57.7，56.2(2)，17.7(2)。HRMS(ESI)+Calculated for C30H32FN4O6，[M+Na]+：m/z 585.2125，found 585.2122。
Compound 29, mp 236-238 ℃, yield 58.0%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.1(1H，s)，8.15(2H，d，J＝8.8Hz)，7.56(1H，dd，J＝14.8，2.4Hz)，7.32(1H，dd，J＝14.8，2.4Hz)，7.14(2H，d，J＝14.8Hz)，7.02(1H，t，J＝9.6Hz)，6.73(1H，d，J＝2.4Hz)，6.53(1H，d，J＝2.4Hz)，4.80(2H，s)，3.89(3H，s)，3.85(3H，s)，3.71-3.74(4H，m)，2.94-2.96(4H，m)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.1，164.5，161.1，160.7，159.6，155.6，153.2，153.0，151.8，135.7(40.6Hz)，133.5(36.0Hz)，129.7(2)，124.3，119.2，115.8，114.7，108.2(100.8Hz)，104.4，100.3，97.6，67.1，66.2(2)，56.1，55.7，50.8(2)。HRMS(ESI)+Calculated for C28H28FN4O6，[M+H]+：m/z 535.1993，found 535.1992。
Compound 30, mp 245-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：11.94(1H，s)，10.16(1H，s)，8.17(2H，d，J＝8.8Hz)，7.55(1H，dd，J＝14.8，2.4Hz)，7.30(2H，dd，J＝8.8，2.4Hz)，7.13(1H，d，J＝2.4Hz)，7.00(1H，t，J＝8.8Hz)，6.71(1H，d，J＝2.4Hz)，6.51(1H，d，J＝2.4Hz)，4.79(2H，s)，3.88(3H，s)，3.84(3H，s)，2.96(4H，t，J＝4.8Hz)，2.46(4H，brs)，2.22(3H，s)；13C-NMR(100MHz，DMSO-d6+CF3COOD)，δ(ppm)：166.2，166.1，163.3，162.8，162.2，157.4，157.0，156.2，153.7，143.2，134.7(42.8Hz)，134.5(36.8Hz)，120.2，118.6，116.0，115.5(2)，108.5(100.8Hz)，103.1，98.9，95.5，67.4，56.8，56.7，56.4，56.3，53.1(2)，47.9。HRMS(ESI)+Calculated for C29H31FN5O5，[M+H]+：m/z 548.2309，found 548.2311。
Compound 31, mp 253-.1H-NMR(400MHz，CDCl3)，δ(ppm)：8.60(1H，s)，7.85(2H，s)，7.58(1H，dd，J＝14.0，2.4Hz)，7.26-7.27(1H，m)，6.94(1H，d，J＝8.8Hz)，6.81(1H，s)，6.44(1H，s)，4.40(2H，s)，3.92(6H，s)，3.10(4H，t，J＝4.4Hz)，2.61(4H，t，J＝4.4Hz)，2.36(9H，s)；13C-NMR(100MHz，CDCl3)，δ(ppm)：166.1，165.2，161.4，157.0，156.7，154.2，153.9，152.3，137.3(36.4Hz)，131.9(36.8Hz)，131.3(2)，129.1，128.5(2)，119.1，115.9，109.2(56.4Hz)，105.0，101.4，98.4，70.5，56.3，55.8，55.2(2)，50.7(2)，46.2，16.5(2)。HRMS(ESI)+Calculated for C31H35FN5O5，[M+H]+：m/z 576.2622，found 576.2624。
Compound 32, mp 273-276 ℃ and yield 62.9%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.29(1H，s)，8.17(2H，d，J＝8.4Hz)，7.85(1H，s)，7.55(1H，d，J＝8.8Hz)，7.21(1H，d，J＝8.8Hz)，7.12(2H，d，J＝8.8Hz)，6.71(1H，s)，6.50(1H，s)，4.81(2H，s)，3.88(3H，s)，3.84(3H，s)，3.30-3.37(8H，m)，2.86(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.3，164.2，160.9，160.3，159.8，153.1，152.3，143.1，135.1，129.3(2)，127.5，125.1，121.3(2)，119.3，114.6(2)，104.5，101.1，97.4，67.0，55.9，55.6，52.9(2)，48.1(2)，42.2。HRMS(ESI)+Calculated for C29H31ClN5O5，[M+H]+：m/z 564.2014，found 564.2011。
Compound 33, mp 260-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.22(1H，s)，7.93(2H，s)，7.91(1H，d，J＝2.4Hz)，7.61(1H，dd，J＝8.8，2.4Hz)，7.14(1H，d，J＝8.8Hz)，6.73(1H，d，J＝2.4Hz)，6.50(1H，d，J＝2.4Hz)，4.49(2H，s)，3.88(3H，s)，3.84(3H，s)，3.17(4H，brs)，2.93(4H，brs)，2.35(6H，s)，2.23(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.6，164.1，160.9，157.6，153.3，153.0，145.0，134.3，130.7(2)，128.4(2)，127.4，121.7，120.8，119.6，104.8，101.0，97.4，79.2，71.0，56.0，55.6，54.9(2)，51.1，48.6，45.8，16.3(2)。HRMS(ESI)+Calculated for C31H35ClN5O5，[M+H]+：m/z 614.2148，found 614.2174。
Compound 34, mp 268-271 ℃, yield 47.6%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：12.17(1H，s)，10.21(1H，s)，8.52(2H，s)，7.88(1H，d，J＝2.4Hz)，7.56(1H，dd，J＝8.8，2.4Hz)，7.16(1H，d，J＝8.8Hz)，6.81(1H，s)，6.56(1H，s)，4.67(2H，s)，3.89(3H，s)，3.85(3H，s)，3.74(4H，t，J＝4.4Hz)，2.94(4H，t，J＝4.0Hz)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：165.1，164.4，160.9，154.0，152.4，149.8，144.8，134.3，132.0(2)，131.3，127.4，122.8，121.7，120.9，119.7，117.7(2)，104.8，101.5，98.2，71.3，66.4(2)，56.1，55.7，51.5(2)。HRMS(ESI)+Calculated for C28H25Br2ClNaN4O6，[M+Na]+：m/z 730.9707，found 730.9714。
Compound 35, mp 247-249 ℃ yield 56.0%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.20(1H，s)，8.15(2H，d，J＝8.8Hz)，7.52(1H，dd，J＝8.8，2.4Hz)，7.13-7.16(3H，m)，6.73(1H，d，J＝2.4Hz)，6.54(1H，d，J＝2.4Hz)，4.81(2H，s)，3.89(3H，s)，3.85(3H，s)，3.73(4H，t，J＝4.4Hz)，2.92(4H，t，J＝4.0Hz)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.1，164.4，161.1，160.6，159.5，153.0，151.8，144.6，134.4，129.7(2)，127.5，124.3，121.4，120.9，119.3，114.7(2)，104.3，100.3，97.6，67.0，66.4(2)，56.0，55.7，51.5(2)。HRMS(ESI)+Calculated for C28H27ClNaN4O6，[M+Na]+：m/z 573.1517，found 573.1533。
Compound 36, mp 258-261 ℃ and yield 51.5%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.17(1H，s)，7.90(3H，s)，7.62(2H，dd，J＝8.8，2.4Hz)，7.15(1H，d，J＝8.8Hz)，6.75(1H，d，J＝2.4Hz)，6.54(1H，d，J＝2.4Hz)，4.49(2H，s)，3.88(3H，s)，3.85(3H，s)，3.73(4H，t，J＝4.4Hz)，2.93(4H，t，J＝4.0Hz)，2.35(6H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：165.5，164.4，161.0，159.5，157.9，152.9，151.9，144.7，134.4，130.9(2)，128.6(2)，127.4，127.2，121.7，120.8，119.6，104.5，100.5，97.7，71.0，66.4(2)，56.0，55.7，51.5(2)，16.2(2)。HRMS(ESI)+Calculated for C30H32ClN4O6，[M+H]+：m/z 579.2010，found 579.2018。
Compound 37, mp 255-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.28(1H，s)，8.18(2H，d，J＝8.8Hz)，7.87(1H，d，J＝2.4Hz)，7.76-7.80(2H，m)，7.70(1H，td，J＝8.8，2.4Hz)，7.56(1H，dd，J＝8.8，2.4Hz)，7.22(1H，d，J＝8.8Hz)，7.15(1H，d，J＝8.8Hz)，3.52(2H，d，J＝11.2Hz)，3.38(2H，d，J＝11.2Hz)，3.19-3.22(2H，m)，3.29(2H，t，J＝13.2Hz)，2.89(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.3，161.8，161.0，158.6，151.4，145.7，143.1，135.1，130.0(32Hz)，129.4(2)，127.5，125.3，123.1(97.2Hz)，121.9(33.2Hz)，121.3(2)，119.3，114.7(2)，110.6(93.2Hz)，67.0，52.8(2)，48.1(2)，42.5。HRMS(ESI)+Calculated for C27H25ClFNaN5O3，[M+Na]+：m/z 544.1528，found 544.1526。
Compound 38, mp 243-245 ℃ and yield 47.7%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：10.28(1H，s)，8.03(2H，d，J＝8.8Hz)，7.85(1H，d，J＝2.4Hz)，7.80(1H，d，J＝8.8Hz)，7.60(1H，d，J＝2.4Hz)，7.51-7.56(2H，m)，7.28(2H，d，J＝8.8Hz)，7.17(1H，d，J＝8.8Hz)，4.88(2H，s)，3.90(3H，s)，3.52(2H，d，J＝12.0Hz)，3.36(2H，d，J＝12.0Hz)，3.21(2H，td，J＝12.0，2.8Hz)，2.97(2H，td，J＝12.0，2.8Hz)，2.87(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.4，162.1，160.0(2)，157.5，149.7，143.1，135.1，129.1(2)，127.5，125.7，124.2，124.1，121.5.121.4，121.3，119.3，114.7(2)，105.9，67.0，55.7，52.9(2)，48.1(2)，42.2。HRMS(ESI)+Calculated for C28H29ClN5O4，[M+H]+：m/z 534.1908，found 534.1899。
Compound 39, mp 281-283 ℃ and yield 54.5 percent.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：12.60(1H，s)，10.30(1H，s)，10.05(1H，s)，8.20(2H，d，J＝8.8Hz)，8.06(1H，d，J＝2.4Hz)，7.86(1H，d，J＝2.4Hz)，7.83(1H，dd，J＝8.8，2.4Hz)，7.72(1H，d，J＝8.8Hz)，7.55(1H，dd，J＝8.8，2.4Hz)，7.22(1H，d，J＝8.8Hz)，7.15(2H，d，J＝8.8Hz)，4.83(2H，s)，3.52-3.55(2H，m)，3.38(2H，d，J＝12.0Hz)，3.18(2H，td，J＝12.0，2.8Hz)，2.99(2H，td，J＝12.0，2.8Hz)，2.89(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.3，161.4，160.5，152.3，147.6，143.1，135.1，134.6，130.3，129.6(2)，129.5，127.5，125.2，124.9，121.9，121.3(2)，119.3，114.7(2)，67.0，52.9(2)，48.1(2)，42.2。HRMS(ESI)+Calculated for C27H26Cl2N5O3，[M+H]+：m/z 538.1413，found 538.1408。
Compound 40, mp 280-.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：12.51(1H，s)，10.18(1H，s)，8.19(2H，d，J＝8.8Hz)，8.12(1H，d，J＝8.8Hz)，7.80(1H，d，J＝2.4Hz)，7.45(1H，d，J＝2.4Hz)，7.51(2H，dd，J＝8.8，2.4Hz)，7.13-7.17(3H，m)，4.81(2H，s)，3.33(4H，brs)，2.91-2.93(4H，m)，2.25(3H，s)；13C-NMR(100MHz，DMSO-d6+CF3COOD)，δ(ppm)：166.3，161.6，160.9，153.6，149.4，143.2，139.4，135.2，129.9(2)，128.1，127.7，126.7，125.9，124.7，121.5，121.4，119.6，119.5，114.9(2)，67.1，53.0(2)，48.2(2)，42.2。HRMS(ESI)+Calculated for C27H26Cl2N5O3，[M+H]+：m/z 538.1413，found 538.1415。
Compound 41, mp 279-282 ℃ and yield 55.5%.1H-NMR(400MHz，DMSO-d6)，δ(ppm)：12.33(1H，s)，10.27(1H，s)，9.91(1H，s)，8.17(1H，d，J＝8.8Hz)，8.01(1H，d，J＝8.4Hz)，7.93(2H，s)，7.85(1H，d，J＝2.4Hz)，7.56(1H，dd，J＝8.8，2.4Hz)，7.52(1H，s)，7.31(1H，dd，J＝8.4，2.4Hz)，7.22(1H，d，J＝8.8Hz)，7.14(1H，d，J＝8.8Hz)，4.82(2H，s)，3.52(2H，d，J＝11.6Hz)，3.38(2H，d，J＝11.6Hz)，3.20(2H，t，J＝12.0Hz)，2.97(2H，t，J＝12.0Hz)，2.88(3H，s)，2.46(3H，s)；13C-NMR(100MHz，DMSO-d6)，δ(ppm)：166.3，162.2，160.3，151.9，148.8，145.0，143.1，135.1，129.4(2)，127.7，127.5，126.8，125.7，125.5，121.3(2)，119.3，118.3，114.7(2)，67.0，52.9(2)，48.1(2)，42.7，21.4。HRMS(ESI)+Calculated for C28H29ClN5O3，[M+H]+：m/z 518.1959，found 518.1953。
Test example 1 Compounds 1-41 were tested for inhibitory activity against BRD4 and CK2 and antiproliferative activity against MDA-MB-231 and MDA-MB-468 cells at a concentration of 1. mu.M.
aCompounds were tested in triplicate. Data are presented as mean ± SD.
bIC50Values were determined by cell viability for 24 hours.
Experimental results show that the compounds of the invention have inhibitory activity on BRD4 and CK2 and inhibitory activity on triple negative breast cancer cell proliferation, wherein the compounds 31, 32, 33, 34 and 35 have good effects, and the optimal compound 32(44e) has stronger inhibitory activity on BRD4 and CK2 and triple negative breast cancer cell inhibitory activity.
Test example 2 Compound 32(44e) induces MDA-MB-231 autophagy in vitro, promoting cell death and apoptosis
The MDA-MB-231 cells were transfected with GFP-mRFP-LC3 adenovirus, and the effect of 44e on the cells was observed by inverted microscopy. It was clearly observed that compound 44e induced the autophagy flux of MDA-MB-231 cells, suggesting that it was able to induce autophagy in MDA-MB-231 cells (FIG. 1A).
The results of the clonogenic experiments show that 44e significantly inhibited the growth and clonogenic activity of MDA-MB-231 cells in a concentration-dependent manner at concentrations of 0. mu.M, 2.5. mu.M, 5. mu.M and 10. mu.M (FIG. 1B).
FIG. 1C MDA-MB-231 cells treated with different concentrations of compound 44e, and after 24h of compound and cell action, both cells were stained with Hoechst 33258 fluorescent dye, and a significant increase in the number of cell deaths was observed in a dose-dependent manner (FIG. 1C).
Test example 3 evaluation of Effect of Compound 32(44e) on in vivo treatment of triple negative Breast cancer
MDA-MB-468 and MDA-MB-231 transplanted tumor models were established and randomly divided into 4 groups of 6 tumors, and an Intragastric administration (Intragastric administration) mode was performed for 19 consecutive days. Both doses of 44e and the drug combination group showed dose-dependent Tumor Growth Inhibition (TGI) effects at the tested doses (fig. 2A, 2B). Particularly, in an MDA-MB-231 transplantation tumor model, when the application dose is 50mg/kg 44e, the inhibition activity is strongest, and the growth inhibition rate is 63.8%.
Claims (7)
1. A dual-targeting BRD4-CK2 small molecule inhibitor, which is characterized in that: a compound of formula I or formula II:
wherein R is1Is 3,5-diCH3H or 3, 5-diBr; r2Is 4-F, 4-OCH34-Cl, 5-Cl or 5-CH3；R3Is composed of
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: the structural formula is shown as formula I.
3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein:
R1is 3,5-diCH3Or H; r3Is composed of
Preferably R1Is H; r3Is composed of
More preferably R1Is H; r3Is composed of
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: the compound of formula I is as follows:
5. use of a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of triple negative breast cancer.
6. Use according to claim 5, characterized in that: the triple negative breast cancer treatment drug is an anti-tumor drug; preferably, the anti-tumor drug is a dual-targeting BRD4-CK2 inhibitor drug.
7. A pharmaceutical composition characterized by: a formulation comprising an effective amount of a compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111046514.7A CN113845484B (en) | 2021-09-07 | 2021-09-07 | Quinazoline small molecule inhibitor and application thereof in antitumor drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111046514.7A CN113845484B (en) | 2021-09-07 | 2021-09-07 | Quinazoline small molecule inhibitor and application thereof in antitumor drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113845484A true CN113845484A (en) | 2021-12-28 |
| CN113845484B CN113845484B (en) | 2023-06-30 |
Family
ID=78973372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111046514.7A Active CN113845484B (en) | 2021-09-07 | 2021-09-07 | Quinazoline small molecule inhibitor and application thereof in antitumor drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113845484B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116396229A (en) * | 2023-04-12 | 2023-07-07 | 四川大学华西医院 | Preparation of a quinazoline compound and its antitumor application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458405A (en) * | 2009-04-22 | 2012-05-16 | 雷斯韦洛吉克斯公司 | Novel anti-inflammatory agents |
| US20130281398A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CN109824693A (en) * | 2017-04-18 | 2019-05-31 | 四川大学 | BRD4 inhibitor and its application in tumor therapy |
-
2021
- 2021-09-07 CN CN202111046514.7A patent/CN113845484B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458405A (en) * | 2009-04-22 | 2012-05-16 | 雷斯韦洛吉克斯公司 | Novel anti-inflammatory agents |
| US20130281398A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CN109824693A (en) * | 2017-04-18 | 2019-05-31 | 四川大学 | BRD4 inhibitor and its application in tumor therapy |
Non-Patent Citations (2)
| Title |
|---|
| VINAY R. SONAWANE，等: "CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors", 《EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
| VINAY SONAWANE，等: "Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116396229A (en) * | 2023-04-12 | 2023-07-07 | 四川大学华西医院 | Preparation of a quinazoline compound and its antitumor application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113845484B (en) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7085566B2 (en) | Apoptosis inducer | |
| JP6315848B2 (en) | MEK / PI3K dual inhibitor and therapeutic method using the inhibitor | |
| AU2013326850B2 (en) | Novel compounds, their preparation and their uses | |
| CN101812059B (en) | nitric oxide donor type farnesyl thiosalicylic acid derivative, preparation method and medical application thereof | |
| CN111410661A (en) | Cap-dependent endonuclease inhibitors and uses thereof | |
| CN103193691B (en) | Sulfonamides compound, pharmaceutical composition and its preparation method and application | |
| JP5649652B2 (en) | Substituted hydrazide compounds and their applications | |
| CN104230952A (en) | Compound containing pyrimidine skeleton, and preparation method and use of compound | |
| CN107903185B (en) | Preparation and application of novel eEF2K inhibitors | |
| CN113845484B (en) | Quinazoline small molecule inhibitor and application thereof in antitumor drugs | |
| US20170183297A1 (en) | Omega-3 analogues | |
| US9399644B2 (en) | [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | |
| CN111138449B (en) | Preparation of dual-targeting ERK1 and ERK5 inhibitors and anti-tumor application thereof | |
| CN114805223B (en) | A kind of 2,4-disubstituted quinazoline compound for inhibiting EGFR and its preparation method and application | |
| JP2013536204A (en) | Dicarboximide derivative of berbamine, its preparation method and use | |
| CN111675647B (en) | 2-indolone PAK1 inhibitor and application thereof in antitumor drugs | |
| JP2023538638A (en) | Pyrazole boronic acid compounds, pharmaceutical compositions containing the same, and uses thereof | |
| CN103864720B (en) | Derived from phenyl acrylic acid farnesyl thio-salicylic acid derivative and preparation method and purposes | |
| CN114671887A (en) | Preparation of indolinone compound and anti-tumor application thereof | |
| CN102670572A (en) | Synthesis and application of bis(2,3-dibromo-4,5-dihydroxybenzyl) ether | |
| WO2016127949A1 (en) | Pyrimidine derivative as inhibitor for t790 mutation | |
| WO2021222738A1 (en) | Compounds for estrogen receptor positive cancers | |
| CN116120254B (en) | 13, 14-Bis-nitric oxide donor-beta-elemene derivative and preparation and application thereof | |
| WO2004039797A1 (en) | A special kind of indole compounds, their preparation, and their use in treatment and prevention of those disease such as cancer | |
| CN111617085B (en) | Targeted HDAC inhibitor and application thereof in antitumor therapeutic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |